Recapping 5 practice-changing FDA decisions from the first half of 2026, including icotrokinra, expanded pediatric indications, and more!
Patrick Campbell
Advertisement
Patrick Campbell is the vice president of content strategy for Dermatology Times and MJH Life Sciences.
Articles by Patrick Campbell
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 1b Trial of FB102 Demonstrates Significant Facial Repigmentation and Sustained Vitiligo Response
2
First Patient Dosed in Phase 2 Trial of Topical Pan-JAK Inhibitor LNK01004 for Vitiligo
3
ICYMI: SkinStylus Gains FDA Clearance for Periorbital Wrinkles Across All Fitzpatrick Skin Types
4
FDA Accepts sNDA for Roflumilast Cream 0.05% in Infants With Atopic Dermatitis Down to 3 Months
5